MedTech Dive September 16, 2024
Elise Reuter

Private equity could be “the most likely” buyer of the eye care business, analysts wrote.

Dive Brief:

  • Bausch + Lomb is exploring a potential sale that would separate the eye care company from parent firm Bausch Health, the Financial Times reported on Saturday, citing unnamed sources.
  • A private equity firm could be a likely buyer, J.P. Morgan and Needham analysts wrote in research notes. “There are only a few strategics that would make sense, in our view, and all would likely run into anti-trust challenges,” Needham analyst David Saxon wrote in a Monday note to clients.
  • Bausch + Lomb received interest from private equity firms before it went public in 2022, the Financial Times reported. A company spokesperson wrote...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Medical Devices, Mergers & Acquisitions / JV, Trends
UN warns of military brain control
Only 20% of AI devices for children used pediatric data to train: 3 notes
Medtech firms have cut thousands of jobs this year. Will layoffs continue in 2025?
Proton therapy market in the US projected to reach $2.67 billion by 2033
How Trump’s second term will affect the medtech industry

Share This Article